The cerebral cortex of the rat possesses 5-HT1A receptor subtype; however, whether the activation of this receptor by dorsal raphe nucleus stimulation produces a similar action on neuronal cortical firing as antidepressants acting on serotonin (5-HT) function is unknown. Single-unit extracellular recordings were obtained from parietal cortex in rats in which dorsal raphe nucleus or cerebellar peduncle was stimulated. Results compared groups long-term treated with clomipramine (1.25 mg/kg i.p., twice a day, during 30 days) or saline (0.15 ml i.p., twice a day, during 30 days). Amplitude of traces, firing rate, and response to treatment with clomipramine proved to be different between cortical neurons responding to dorsal raphe nucleus or cerebellar peduncle stimulation. Clomipramine increased a long-lasting cortical suppression of firing elicited by dorsal raphe nucleus stimulation. Obtained data suggests that the responses of nearby cortical neurons containing different kinds of 5-HT receptors may relate to the involved pathways and that clomipramine seems to act on 5-HT1A receptor subtype.

Keywords:
Clomipramine, Serotonin, Serotonin receptors, Tricyclic, Raphe nuclei, Cerebral cortex
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.